Thrombosis in inflammatory bowel diseases: What's the link?

被引:100
作者
Giannotta M. [1 ]
Tapete G. [1 ]
Emmi G. [2 ]
Silvestri E. [2 ]
Milla M. [1 ]
机构
[1] AOU Careggi Regional Referral Center for Inflammatory Bowel Disease, Gastroenterology Department, Florence
[2] University of Florence and Patologia Medica Unit, AOU Careggi, Department of Experimental and Clinical Medicine, Florence
关键词
Crohn's disease; Inflammatory bowel disease; Thrombosis; Ulcerative colitis;
D O I
10.1186/s12959-015-0044-2
中图分类号
学科分类号
摘要
Inflammatory bowel disease affects more than 2 million people in Europe, with almost 20% of patients being diagnosed in pediatric age. Patients with inflammatory bowel disease are at increased risk of thromboembolic complications which may affect patients' morbidity and mortality. The risk of the most common thromboembolic events, such as deep venous thrombosis and pulmonary embolism, are estimated to be three-fold increased compared to controls, but many other districts can be affected. Moreover, patients with ulcerative colitis and Crohn's disease experience thromboembolic events at a younger age compared to general population. Many factors have been investigated as determinants of the pro-thrombotic tendency such as acquired risk factors or genetic and immune abnormalities, but a unique cause has not been found. Many efforts have been focused on the study of abnormalities in the coagulation cascade, its natural inhibitors and the fibrinolytic system components and both quantitative and qualitative alterations have been demonstrated. Recently the role of platelets and microvascular endothelium has been reviewed, as the possible link between the inflammatory and hemostatic process. © Giannotta et al.
引用
收藏
相关论文
共 112 条
[51]  
Hayat M., Ariens R.A., Moayyedi P., Grant P.J., O'Mahony S., Coagulation factor XIII and markers of thrombin generation and fibrinolysis in patients with inflammatory bowel disease, Eur J Gastroenterol Hepatol, 14, pp. 249-256, (2002)
[52]  
Diamant M., Tushuizen M.E., Sturk A., Nieuwland R., Cellular microparticles: New players in the field of vascular disease?, Eur J Clin Invest, 34, pp. 392-401, (2004)
[53]  
Andoh A., Tsujikawa T., Hata K., Araki Y., Kitoh K., Sasaki M., Et al., Elevated circulating platelet-derived microparticles in patients with active inflammatory bowel disease, Am J Gastroenterol, 100, pp. 2042-2048, (2005)
[54]  
Esmon C.T., The interactions between inflammation and coagulation, Br J Haematol, 131, pp. 417-430, (2005)
[55]  
Owczarek D., Cibor D., Glowacki M.K., Rodacki T., Mach T., Inflammatory bowel disease: Epidemiology, pathology and risk factors for hyper coagulability, World J Gastroenterol, 20, pp. 53-63, (2014)
[56]  
Scaldaferri F., Lancellotti S., Pizzoferrato M., Cristofaro R., Haemostatic system in inflammatory bowel disease: new players in gut inflammation, World J Gastroenterol, 17, pp. 594-608, (2011)
[57]  
Ghosh S., Mackie M.J., McVerry B.A., Galloway M., Ellis A., McKay J., Chronic inflammatory bowel disease, deep-venous thrombosis and antithrombin activity, Acta Haematol, 70, pp. 50-53, (1983)
[58]  
Heneghan M.A., Cleary B., Murray M., O'Gorman T.A., McCarthy C.F., Activated protein C resistance, thrombophilia, and inflammatory bowel disease, Dig Dis Sci, 43, pp. 1356-1361, (1998)
[59]  
Yurekli B.P., Aksoy D.Y., Aybar M., Egesel T., Gurgey A., Has-celik G., Et al., The search for a common thrombophilic state during the active state of inflammatory bowel disease, J Clin Gastroenterol, 40, pp. 809-813, (2006)
[60]  
Aadland E., Odegaard O.R., Roseth A., Try K., Free protein S deficiency in patients with chronic inflammatory bowel disease, Scand J Gastroenterol, 27, pp. 957-960, (1992)